第一个针对基孔肯雅病毒(CHIKV)的疫苗最近在美国获得许可,欧洲,和加拿大(IXCHIQ®品牌,称为VLA1553)。其他致病性甲病毒与CHIKV共同传播,关于IXCHIQ为暴露于它们的人群提供交叉保护的潜力,主要问题仍然存在。这里,我们在1个月时对个体中针对异型CHIKV和额外的关节炎性α病毒的交叉中和抗体(nAb)应答进行了表征,六个月,和IXCHIQ疫苗接种后一年。我们针对CHIKV菌株LR2006,181/25和来自Tocantins的2021分离株鉴定了nAbs,巴西,以及O\'nyong-nyong病毒(ONNV),Mayaro病毒(MAYV),罗斯河病毒(RRV)IXCHIQ引起每种病毒的100%血清转化,除了接种疫苗83.3%的RRV,交叉中和抗体效价随着与CHIKV遗传距离的增加而降低。我们比较了感染后8-9年生活在波多黎各地方性环境中的个体对自然CHIKV感染引起的交叉nAbs的疫苗反应。这些数据表明,IXCHIQ有效和有效地引发交叉nAb宽度,以类似于自然CHIKV感染的方式延伸到相关甲病毒,这可能对在潜在疫苗推广地区易受甲病毒共循环影响的个体具有重要意义。
The first vaccine against chikungunya virus (CHIKV) was recently licensed in the U.S., Europe, and Canada (brand IXCHIQ®, referred to as VLA1553). Other pathogenic
alphaviruses co-circulate with CHIKV and major questions remain regarding the potential of IXCHIQ to confer cross-protection for populations that are exposed to them. Here, we characterized the cross-neutralizing antibody (nAb) responses against heterotypic CHIKV and additional arthritogenic
alphaviruses in individuals at one month, six months, and one year post-IXCHIQ vaccination. We characterized nAbs against CHIKV strains LR2006, 181/25, and a 2021 isolate from Tocantins, Brazil, as well as O\'nyong-nyong virus (ONNV), Mayaro virus (MAYV), and Ross River virus (RRV). IXCHIQ elicited 100% seroconversion to each virus, with the exception of RRV at 83.3% seroconversion of vaccinees, and cross-neutralizing antibody potency decreased with increasing genetic distance from CHIKV. We compared vaccinee responses to cross-nAbs elicited by natural CHIKV infection in individuals living in the endemic setting of Puerto Rico at 8-9 years post-infection. These data suggest that IXCHIQ efficiently and potently elicits cross-nAb breadth that extends to related
alphaviruses in a manner similar to natural CHIKV infection, which may have important implications for individuals that are susceptible to alphavirus co-circulation in regions of potential vaccine rollout.